Drug · CHEMBL87992
ESLICARBAZEPINE ACETATE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ESLICARBAZEPINE ACETATE. Drugs and targets, record CHEMBL87992. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL87992
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 2 of its 8 diseases, from DailyMed and EMA Human Drugs
- Open Targets
Targets10
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| SCN10A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6336 |
| SCN11A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/11280 |
| SCN1A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6323 |
| SCN2A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6326 |
| SCN3A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6328 |
| SCN4A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6329 |
| SCN5A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6331 |
| SCN7A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6332 |
| SCN8A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6334 |
| SCN9A | Sodium channel alpha subunit | Sodium channel alpha subunit blocker | BLOCKER | https://conductscience.org/library/genes/6335 |
Source ChEMBL
Diseases8
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| Focal-onset seizure | Phase 3 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=HP_0007359 |
| focal epilepsy | Phase 3 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0005384 |
| epilepsy | Approval | EMA Human Drugs | 4 | 2 | https://conductscience.org/library/drugs?q=MONDO_0005027 |
| Seizure | Approval | DailyMed | 2 | 1 | https://conductscience.org/library/drugs?q=HP_0001250 |
| Focal impaired awareness seizure | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0002384 |
| bipolar I disorder | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=EFO_0009963 |
| diabetic neuropathy | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0006626 |
| fibromyalgia | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005546 |
Source Open Targets
Trials65
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00988429 | Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures | Phase 3 | 653 | 2014-04-15 | eslicarbazepine acetate | Its name | ClinicalTrials.gov |
| NCT00981227 | Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia | Phase 2 | 567 | 2013-05-03 | eslicarbazepine acetate | Its name | ClinicalTrials.gov |
| NCT00980746 | Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy | Phase 2 | 557 | 2013-05-22 | eslicarbazepine acetate | Its name | ClinicalTrials.gov |
| NCT01820585 | Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia | Phase 2 | 528 | 2013-07-19 | eslicarbazepine acetate | Its name | ClinicalTrials.gov |
| NCT01820559 | Efficacy and Safety of Eslicarbazepine Acetate as Preventive Therapy for Subjects With Migraine | Phase 2 | 452 | 2013-05-24 | eslicarbazepine acetate | Its name | ClinicalTrials.gov |
| NCT00957684 | Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures | Phase 3 | 402 | 2013-10-10 | eslicarbazepine acetate | Its name | ClinicalTrials.gov |
| NCT00957047 | Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy | Phase 3 | 395 | 2013-08-05 | eslicarbazepine acetate | Its name | ClinicalTrials.gov |
| NCT01129960 | Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain | Phase 3 | 332 | 2014-07-18 | eslicarbazepine acetate | Its name | ClinicalTrials.gov |
| NCT00988156 | Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children | Phase 3 | 304 | 2014-07-17 | eslicarbazepine acetate | Its name | ClinicalTrials.gov |
| NCT00910247 | Eslicarbazepine Acetate Monotherapy Long Term Study | Phase 3 | 274 | 2018-07-17 | eslicarbazepine acetate | Its name | ClinicalTrials.gov |
1 to 10 of 65
See all 65 trialsComparisons in its trials20
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Esl (BIA 2-093) vs Placebo: Responder Rate | 41 of 134 | 40 of 129 | 263 | NCT00988156 | Trial comparisons |
| Esl (Safety Set Part I) vs Placebo (Safety Set Part I): serious adverse events | 15 of 134 | 9 of 129 | 263 | NCT00988156 | Trial comparisons |
| Eslicarbazepine 1200 mg QD vs Eslicarbazepine 1600 mg QD: serious adverse events | 4 of 65 | 8 of 128 | 193 | NCT00866775 | Trial comparisons |
| ESL1200 mg vs ESL 1600 mg: serious adverse events | 1 of 58 | 8 of 114 | 172 | NCT01091662 | Trial comparisons |
| Group A vs Group B: deaths from any cause | 6 of 61 | 0 of 62 | 123 | NCT06597084 | Trial comparisons |
| Group A vs Group B: serious adverse events | 12 of 61 | 13 of 62 | 123 | NCT06597084 | Trial comparisons |
| Eslicarbazepine Acetate (Arm 1) vs Eslicarbazepine Acetate (Arm 2): The Number of Subjects Completing 24 Weeks Adjunctive Therapy During Maintenance Phase | 36 of 44 | 37 of 58 | 102 | NCT03116828 | Trial comparisons |
| Arm 1 vs Arm 2: deaths from any cause | 0 of 44 | 0 of 58 | 102 | NCT03116828 | Trial comparisons |
| Arm 1 vs Arm 2: serious adverse events | 0 of 44 | 4 of 58 | 102 | NCT03116828 | Trial comparisons |
| Eslicarbazepine vs Carbamazepine: deaths from any cause | 0 of 29 | 0 of 30 | 59 | NCT02912364 | Trial comparisons |
1 to 10 of 20
See all 20 comparisons in its trialsPapers from its trials5
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials1
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome |
|---|---|---|
| Choice Reaction Time | 1 | 1 |
Source ConductCognition
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL87992
GET https://conductscience.org/api/drugs/v1/CHEMBL87992/trials?page=2